Rhabdomyosarcoma 2 (RMS2) Cell Models for Research

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, accounting for approximately 3% of all childhood cancers. The World Health Organization (WHO) classifies RMS into two major subtypes: alveolar (ARMS) and embryonal (ERMS). Rhabdomyosarcoma 2 (RMS2) is a specific genetic subtype often associated with the PAX3-FOXO1 fusion, which occurs in about 55-70% of ARMS cases. The incidence of RMS is approximately 4.5 cases per million children per year in the United States, with a slight male predominance. The 5-year survival rate for localized disease is around 70-80%, but for metastatic disease, it drops to less than 30% (NCI SEER data). Risk factors include genetic syndromes such as Li-Fraumeni, neurofibromatosis type 1, and Beckwith-Wiedemann syndrome. The clinical impact is severe due to aggressive progression and limited targeted therapies, especially for fusion-positive RMS.

RMS2 is an ideal model for mechanistic studies due to its well-defined genetic drivers, such as PAX3-FOXO1 and RAS pathway mutations. Public datasets from TCGA and COSMIC provide extensive genomic and transcriptomic data, enabling researchers to identify novel therapeutic targets. Open questions include the role of the fusion protein in chromatin remodeling and the mechanisms of drug resistance. Gene-edited cell models allow precise manipulation of these genetic alterations to study their functional consequences, making RMS2 a powerful system for drug discovery and functional genomics.

RMS2 pathogenesis is driven by several key pathways:

• • PAX3-FOXO1 fusion protein: Acts as an aberrant transcription factor, upregulating genes involved in cell proliferation, survival, and migration.
• • RAS/MAPK pathway: Mutations in NRAS, KRAS, or HRAS are found in a subset of RMS, leading to constitutive activation of the MAPK cascade.
• • PI3K/AKT/mTOR pathway: Frequently activated due to PTEN loss or PI3K mutations, promoting cell growth and survival.
• • WNT/β-catenin pathway: Deregulated in some RMS, contributing to stemness and differentiation blockade.

These pathways interact to maintain the malignant phenotype and are targets for therapeutic intervention.

Data compiled from TCGA and COSMIC databases.

Key signaling networks in RMS2 include:

• • MAPK/ERK pathway: RAS mutations lead to sustained ERK activation, promoting proliferation.
• • PI3K/AKT pathway: PTEN loss or PI3K mutations activate AKT, inhibiting apoptosis.
• • WNT/β-catenin: Nuclear β-catenin accumulation activates TCF/LEF transcription factors, driving stemness.
• • Hedgehog pathway: Aberrant activation in some RMS, contributing to tumor growth.
• • Notch signaling: Involved in cell fate decisions and may be deregulated.

These networks provide multiple nodes for targeted therapy and are the basis for combination drug screening.

Organoids derived from patient tumors retain the genetic heterogeneity and 3D architecture, providing a more physiologically relevant platform for drug testing. They can be genetically engineered using CRISPR to introduce or correct mutations, enabling functional studies.

Animal models for RMS2 include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice, preserving the original tumor's genetic and phenotypic features.
• • Genetically engineered mouse models (GEMM): Conditional expression of PAX3-FOXO1 in muscle progenitor cells leads to RMS development.
• • Induced models: Use of viral vectors or CRISPR to introduce oncogenic mutations in mouse muscle cells.

These models are essential for studying tumor progression, metastasis, and evaluating novel therapies in vivo.

CRISPR-based gene editing allows the creation of isogenic cell lines with specific genetic alterations, such as TP53 knockout or KRAS G12D knock-in. These models are commercially available and sequence-verified, ensuring reproducibility and reliability. They enable researchers to study the direct impact of a single mutation on cellular phenotype, drug response, and signaling pathways. For example, a PAX3-FOXO1 knockout in RH30 cells can reveal downstream target genes, while a TP53 knockout in RD cells can model loss-of-function and test p53 reactivation drugs. Such models are indispensable for functional genomics and drug discovery.

Gene-edited cell lines are used to validate the function of genes implicated in RMS2. For example:

• • CRISPR knockout of PAX3-FOXO1 in RH30 cells reduces proliferation and induces differentiation, confirming its oncogenic role.
• • Knock-in of a RAS mutation in an embryonal RMS cell line can transform it to a more aggressive phenotype.
• • Loss-of-function screens using CRISPR libraries can identify genes essential for RMS2 survival, revealing novel therapeutic targets.

Isogenic cell line pairs (e.g., TP53 wild-type vs. knockout) are used to screen for compounds that selectively kill cancer cells while sparing normal cells. They also model acquired resistance by exposing cells to increasing drug concentrations and identifying resistance mutations. For example, a PAX3-FOXO1 inhibitor can be tested on isogenic lines with and without the fusion to determine specificity. This approach accelerates the development of targeted therapies and combination strategies.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in the presence of a specific mutation (e.g., PAX3-FOXO1). This approach uncovers vulnerabilities that can serve as biomarkers for patient stratification. Additionally, gene-edited models can be used to validate candidate biomarkers by modulating their expression and assessing correlation with drug response.